Glaukos (GKOS) Stock Price, News & Analysis

Company Overview

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Key Stats

• Today's Range: $93.28 to $94.91
• 50-Day Range: $90.99 to $106.65
• 52-Week Range: $77.10 to $163.71
• Volume: 315,608 shs
• Average Volume: 912,679 shs
• Market Capitalization: $5.39 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $134.67
• Consensus Rating: Moderate Buy

Glaukos Stock Analysis - MarketRank™

Glaukos scored higher than 88% of companies evaluated by MarketBeat, and ranked 124th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Glaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 10 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Glaukos has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Glaukos are expected to grow in the coming year, from ($1.08) to ($0.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Glaukos is -39.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Glaukos is -39.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Glaukos has a P/B Ratio of 6.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.23% of the float of Glaukos has been sold short.

Short Interest Ratio / Days to Cover

Glaukos has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Glaukos has recently increased by 24.87%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Glaukos does not currently pay a dividend.

Dividend Growth

Glaukos does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -0.90

Percentage of Shares Shorted

9.23% of the float of Glaukos has been sold short.

Short Interest Ratio / Days to Cover

Glaukos has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Glaukos has recently increased by 24.87%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.05

News Sentiment

Glaukos has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Glaukos this week, compared to 7 articles on an average week.

Search Interest

4 people have searched for GKOS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

3 people have added Glaukos to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Glaukos insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.80% of the stock of Glaukos is held by insiders.

Percentage Held by Institutions

99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GKOS Stock Analysis - Frequently Asked Questions

How have GKOS shares performed this year?

Glaukos' stock was trading at $149.94 at the beginning of the year. Since then, GKOS stock has decreased by 37.0% and is now trading at $94.4140.

How were Glaukos' earnings last quarter?

Glaukos Corporation (NYSE:GKOS) posted its quarterly earnings results on Wednesday, April, 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11. The business's revenue was up 24.6% compared to the same quarter last year.
Read the conference call transcript.

When did Glaukos IPO?

Glaukos (GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Who are Glaukos' major shareholders?

Top institutional shareholders of Glaukos include Riverbridge Partners LLC (0.71%), Blair William & Co. IL (0.08%), Harbor Capital Advisors Inc. (0.07%) and State of Alaska Department of Revenue (0.06%). Insiders that own company stock include Joseph E Gilliam, Tomas Navratil, Thomas William Burns, Alex R Thurman, Marc Stapley, Mark J Foley, Gilbert H Kliman and Aimee S Weisner.
View institutional ownership trends.

How do I buy shares of Glaukos?

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Glaukos investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA) and Netflix (NFLX).

Company Calendar

• Last Earnings: 4/30/2025
• Today: 7/25/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:GKOS
• CIK: 1192448
• Web: www.glaukos.com
• Phone: (949) 367-9600
• Fax: 949-367-9984
• Employees: 780
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Glaukos: $134.67
• High Price Target: $182.00
• Low Price Target: $72.00
• Potential Upside/Downside: +42.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$146.37 million
• Net Margins: -31.40%
• Pretax Margin: -30.40%
• Return on Equity: -10.66%
• Return on Assets: -8.06%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 6.49
• Quick Ratio: 5.62

Sales & Book Value

• Annual Sales: $383.48 million
• Price / Sales: 14.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.91 per share
• Price / Book: 6.79

Miscellaneous

• Outstanding Shares: 57,140,000
• Free Float: 53,827,000
• Market Cap: $5.40 billion
• Optionable: Optionable
• Beta: 0.82